Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis

Trial Profile

A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavrilimumab (Primary) ; Prednisone
  • Indications Giant cell arteritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Kiniksa Pharmaceuticals
  • Most Recent Events

    • 12 Jun 2019 According to an Kiniksa Pharmaceuticals media release, the company looks forward to present top-line data from this trial in the second half of 2020.
    • 31 Jan 2019 Status changed from suspended to recruiting.
    • 06 Dec 2018 According to a Kiniksa Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) requested additional information regarding the delivery device to be used in this study. In light of its device-related information request, the FDA has placed the company's recently-submitted IND on clinical hold.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top